Share on StockTwits

Horizon Pharma (NASDAQ:HZNP) is scheduled to release its Q114 earnings data on Friday, May 9th. Analysts expect Horizon Pharma to post earnings of $0.01 per share and revenue of $42.69 million for the quarter. Horizon Pharma has set its FY14 guidance at profitability EPS.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.14. The company had revenue of $43.10 million for the quarter, compared to the consensus estimate of $32.20 million. The company’s revenue for the quarter was up 370.3% on a year-over-year basis. On average, analysts expect Horizon Pharma to post $0.50 EPS for the current fiscal year and $1.16 EPS for the next fiscal year.

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 13.40 on Thursday. Horizon Pharma has a 52-week low of $2.11 and a 52-week high of $18.30. The stock has a 50-day moving average of $14.39 and a 200-day moving average of $9.81. The company’s market cap is $907.6 million.

A number of research firms have recently commented on HZNP. Analysts at JMP Securities cut their price target on shares of Horizon Pharma from $22.00 to $21.00 in a research note on Friday, March 28th. They now have an “outperform” rating on the stock. On a related note, analysts at Stifel Nicolaus raised their price target on shares of Horizon Pharma from $18.00 to $25.00 in a research note on Friday, March 28th. Finally, analysts at TheStreet downgraded shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.93.

Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.